Where can I find NBIO's financial statements?

Nascent Biotech, Inc. (NBIO)'s full income statement, balance sheet, and cash flow statement are on this page in 10-K-style line-item format. Switch between the three statements via the pill toggle above the table.

How much history is available for NBIO?

Nascent Biotech, Inc. (NBIO) statements are available back to its earliest filed 10-K — typically 10+ years of annual data and 40 quarters of quarterly data. Free-tier users see 5 years and 8 quarters; full history unlocks with a Pro account.

How often does NBIO update its statements?

Nascent Biotech, Inc. files a 10-K annually (full audited year-end statements) and 10-Q reports quarterly (unaudited interim statements). New filings are typically parsed and reflected on this page within 48 hours of SEC submission.

NBIO

Nascent Biotech, Inc.

OTC·Biotechnology · Healthcare

$0.00$0.00+0.00%

Market cap$51.67K·Market closed·Aug 25 8:00 PM UTC

USD · values shown as reported

Line item	FY 2020	FY 2021	FY 2022	FY 2023	FY 2024	Trend
Revenue	$0.00	$750.00K	$1.00M+33.3%	$0.00−100.0%	$0.00
Cost of revenue	—	—	—	—	$319.51K	—
Gross profit	$0.00	$750.00K	$1.00M+33.3%	$0.00−100.0%	−$320.00K
Research & development	$293.71K+15.6%	$321.94K+9.6%	$197.41K−38.7%	$654.22K+231.4%	$203.44K−68.9%
General & administrative	$3.15M+182.9%	$1.83M−42.0%	$927.36K−49.3%	$1.50M+61.9%	$1.71M+13.7%
SG&A (combined)	$3.15M+182.9%	$1.83M−42.0%	$927.36K−49.3%	$1.50M+61.9%	$1.71M+13.7%
Other operating expenses	−$709.00	$62.00+108.7%	$332.24K+535,766.1%	—	−$441.00
Total operating expenses	$3.45M+151.8%	$2.15M−37.6%	$1.46M−32.2%	$2.16M+48.0%	$1.91M−11.4%
Operating income	−$3.45M−151.8%	−$1.40M+59.4%	−$457.00K+67.4%	−$2.16M−371.8%	−$2.23M−3.4%
Interest income	$6.00−85.4%	$5.00−16.7%	$12.00+140.0%	$274.00+2,183.3%	$5.27K+1,821.5%
Interest expense	$86.63K	$356.04K+311.0%	$487.17K+36.8%	$1.72M+253.7%	$385.24K−77.6%
Other income / (expense), net	−$557.00K−1,358,636.6%	$441.60K+179.3%	−$13.34K−103.0%	−$645.00K−4,735.8%	$142.20K+122.0%
Income before tax	−$4.00M−192.5%	−$959.00K+76.0%	−$470.00K+51.0%	−$2.80M−496.0%	−$2.09M+25.5%
Net income	−$4.00M−192.5%	−$959.00K+76.0%	−$470.00K+51.0%	−$2.80M−496.0%	−$2.09M+25.5%

EPS (basic)	−$0.12−163.7%	−$0.01+88.9%	−$0.00+66.9%	−$0.02−436.4%	−$0.01+43.2%
EPS (diluted)	−$0.12−163.7%	−$0.01+88.9%	−$0.00+66.9%	−$0.02−436.4%	−$0.01+43.2%
Weighted avg shares (basic)	34,393,000	72,342,000	107,742,000	118,569,000	155,744,000
Weighted avg shares (diluted)	34,393,000	72,342,000	107,742,000	118,569,000	155,744,000

Depreciation & amortization	$3.45M+151.8%	$1.40M−59.4%	$457.05K−67.4%	$2.16M+371.7%	$2.23M+3.4%
EBITDA	−$470.00K−1,146,441.5%	−$602.72K−28.2%	$16.78K+102.8%	−$1.07M−6,491.6%	$527.43K+149.2%

Frequently Asked Questions About NBIO

Where can I find NBIO's financial statements?: Nascent Biotech, Inc. (NBIO)'s full income statement, balance sheet, and cash flow statement are on this page in 10-K-style line-item format. Switch between the three statements via the pill toggle above the table.
How much history is available for NBIO?: Nascent Biotech, Inc. (NBIO) statements are available back to its earliest filed 10-K — typically 10+ years of annual data and 40 quarters of quarterly data. Free-tier users see 5 years and 8 quarters; full history unlocks with a Pro account.
How often does NBIO update its statements?: Nascent Biotech, Inc. files a 10-K annually (full audited year-end statements) and 10-Q reports quarterly (unaudited interim statements). New filings are typically parsed and reflected on this page within 48 hours of SEC submission.

Line item

FY 2020

FY 2021

FY 2022

FY 2023

FY 2024

Trend

Revenue

$0.00

$750.00K

$1.00M+33.3%

$0.00−100.0%

$0.00

Cost of revenue

—

$319.51K

—

Gross profit

$0.00

$750.00K

$1.00M+33.3%

$0.00−100.0%

−$320.00K

Research & development

$293.71K+15.6%

$321.94K+9.6%

$197.41K−38.7%

$654.22K+231.4%

$203.44K−68.9%

General & administrative

$3.15M+182.9%

$1.83M−42.0%

$927.36K−49.3%

$1.50M+61.9%

$1.71M+13.7%

SG&A (combined)

$3.15M+182.9%

$1.83M−42.0%

$927.36K−49.3%

$1.50M+61.9%

$1.71M+13.7%

Other operating expenses

−$709.00

$62.00+108.7%

$332.24K+535,766.1%

—

−$441.00

Total operating expenses

$3.45M+151.8%

$2.15M−37.6%

$1.46M−32.2%

$2.16M+48.0%

$1.91M−11.4%

Operating income

−$3.45M−151.8%

−$1.40M+59.4%

−$457.00K+67.4%

−$2.16M−371.8%

−$2.23M−3.4%

Interest income

$6.00−85.4%

$5.00−16.7%

$12.00+140.0%

$274.00+2,183.3%

$5.27K+1,821.5%

Interest expense

$86.63K

$356.04K+311.0%

$487.17K+36.8%

$1.72M+253.7%

$385.24K−77.6%

Other income / (expense), net

−$557.00K−1,358,636.6%

$441.60K+179.3%

−$13.34K−103.0%

−$645.00K−4,735.8%

$142.20K+122.0%

Income before tax

−$4.00M−192.5%

−$959.00K+76.0%

−$470.00K+51.0%

−$2.80M−496.0%

−$2.09M+25.5%

Net income

−$4.00M−192.5%

−$959.00K+76.0%

−$470.00K+51.0%

−$2.80M−496.0%

−$2.09M+25.5%

EPS (basic)

−$0.12−163.7%

−$0.01+88.9%

−$0.00+66.9%

−$0.02−436.4%

−$0.01+43.2%

EPS (diluted)

−$0.12−163.7%

−$0.01+88.9%

−$0.00+66.9%

−$0.02−436.4%

−$0.01+43.2%

Weighted avg shares (basic)

34,393,000

72,342,000

107,742,000

118,569,000

155,744,000

Weighted avg shares (diluted)

34,393,000

72,342,000

107,742,000

118,569,000

155,744,000

Depreciation & amortization

$3.45M+151.8%

$1.40M−59.4%

$457.05K−67.4%

$2.16M+371.7%

$2.23M+3.4%

EBITDA

−$470.00K−1,146,441.5%

−$602.72K−28.2%

$16.78K+102.8%

−$1.07M−6,491.6%

$527.43K+149.2%